Showing results (31-40 of 297) with videos related to
Sort By:
Pageof 30
Pharmacogenetics|August 2, 2003
UGT pharmacogenomics: implications for cancer risk and cancer therapeuticsApurva A Desai, Federico Innocenti, Mark J RatainTrends in Pharmacological Sciences|July 4, 2006
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?Michael L Maitland, Kaveeta Vasisht, Mark J RatainBritish Journal of Clinical Pharmacology|April 5, 2021
Influence of N-acetyltransferase 2 gene polymorphisms on the in vitro metabolism of the epidermal growth factor receptor inhibitor rociletinibJacqueline Ramirez, Larry K House, Mark J RatainJAMA Network Open|April 13, 2026
Negative Descriptors of Patients With Sickle Cell Disease in the Electronic Health RecordAustin Wesevich, Alexandria Vangelatos, Michael Sun, et al.Pharmacotherapy|May 28, 2008
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?Minoli A Perera, Federico Innocenti, Mark J RatainJournal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
Interpreting disparate responses to cancer therapy: the role of human population geneticsMichael L Maitland, Anna DiRienzo, Mark J RatainBritish Journal of Clinical Pharmacology|July 18, 2006
The role of pharmacogenetics in cancer therapeuticsWei Peng Yong, Federico Innocenti, Mark J RatainPlos One|April 27, 2007
Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoformsWei Zhang, Wanqing Liu, Federico Innocenti, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 24, 2009
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferasesYong Liu, Jacqueline Ramírez, Larry House, et al.Nature Reviews. Cancer|June 2, 2005
Pharmacokinetic variability of anticancer agentsSamir D Undevia, Gonzalo Gomez-Abuin, Mark J RatainPageof 30